SAI
ATNM icon

Savvy Advisors Inc’s Actinium Pharmaceuticals ATNM Stock Holding History

Savvy Advisors Inc’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.95K Hold
10,000
– – ﹤0.01% 1138
2025
Q4 		$13.6K Buy
+10,000
New +$14.6K ﹤0.01% 1008

Other funds holding ATNM

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Savvy Advisors Inc's ATNM Position: Q1 2026 in Review

Savvy Advisors Inc held its Actinium Pharmaceuticals (ATNM) position steady in Q1 2026 at 10,000 shares worth $9.95K. The position accounts for ﹤0.01% of the portfolio, ranked #1138.

Savvy Advisors Inc first reported a position in ATNM in Q4 2025 and has held it in 2 quarters since. The position peaked at $13.6K in Q4 2025. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

  • Savvy Advisors Inc held 10,000 shares of Actinium Pharmaceuticals worth $9.95K as of Q1 2026.
  • Savvy Advisors Inc left its Actinium Pharmaceuticals share count unchanged in Q1 2026.
  • Actinium Pharmaceuticals made up ﹤0.01% of Savvy Advisors Inc's portfolio in Q1 2026, its #1138 holding.
  • Savvy Advisors Inc first reported a position in Actinium Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Savvy Advisors Inc's Actinium Pharmaceuticals position peaked at $13.6K in Q4 2025.
  • 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on Savvy Advisors Inc's 13F filing for Q1 2026, filed 11 May 2026.